+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Cancer Monoclonal Antibodies"

Precision Cancer Therapeutics, 2022 - Product Thumbnail Image

Precision Cancer Therapeutics, 2022

  • Report
  • November 2022
  • 154 Pages
  • Global
From
CAR-T Cell Therapy Market Review - Product Thumbnail Image

CAR-T Cell Therapy Market Review

  • Report
  • December 2019
  • 59 Pages
  • Global
From
From
From
From
From
From
From
Global Bispecific Antibodies for Cancer Market 2023-2027 - Product Thumbnail Image

Global Bispecific Antibodies for Cancer Market 2023-2027

  • Report
  • February 2023
  • 155 Pages
  • Global
From
Targeted Oncology Therapeutics: Hematology Cancers - Product Thumbnail Image

Targeted Oncology Therapeutics: Hematology Cancers

  • Report
  • October 2021
  • 110 Pages
  • Global
From
Drug Delivery in Cancer - Technologies, Markets & Companies - Product Thumbnail Image

Drug Delivery in Cancer - Technologies, Markets & Companies

  • Report
  • November 2021
  • 747 Pages
  • Global
From
From
Loading Indicator

Cancer Monoclonal Antibodies (mAbs) are a type of oncology drug used to treat cancer. They are a type of biologic therapy, which means they are made from living cells. mAbs are designed to target specific proteins on cancer cells, which can help to slow or stop the growth of the cancer. They can be used alone or in combination with other treatments, such as chemotherapy or radiation therapy. mAbs can be used to treat a variety of cancers, including breast, lung, and colorectal cancer. The Cancer Monoclonal Antibodies market is a rapidly growing segment of the oncology drugs market. mAbs are becoming increasingly popular due to their ability to target specific proteins on cancer cells, which can help to reduce side effects and improve outcomes. Additionally, mAbs are often more cost-effective than other treatments, making them attractive to healthcare providers. Some of the major companies in the Cancer Monoclonal Antibodies market include Roche, Merck, Bristol-Myers Squibb, Amgen, and Novartis. Show Less Read more